Crown Laboratories, Revance Amend A&R Merger Agreement; Increases Offer Price To $3.65/shr
Crown Laboratories and Revance Therapeutics (RVNC) announced that, on January 17, 2025, they amended their previously announced ...
Revance, Crown Laboratories amend merger agreement to increase offer price
Crown Laboratories and Revance Therapeutics announced that, on January 17, they amended their previously announced amended and restated merger agreement. Under the terms of the se ...
Revance Therapeutics Accepts Crown Increased Takeover Bid
Revance on Tuesday said it signed a revised merger agreement with privately held Crown, which has extended its tender offer for the Nashville, Tenn., biotechnology company to Feb. 4. Crown raised its ...
Crown Laboratories hikes offer price for Revance to $3.65/share, extends existing tender offer
Crown Laboratories Tuesday increased its offer price to acquire Revance Therapeutics (NASDAQ:RVNC) to $3.65 per share, a $0.55 per share increase. Improved offer unanimously approved by Revance ...